June 26, 2020, HOUSTON — Celltex, a Houston, Texas-based biotechnology company, announced that it has received approval from the U.S. Food and Drug Administration (FDA) to proceed with the Company’s Investigational New Drug application (IND 22055) to investigate the Prophylactic Efficacy of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) Against Coronavirus Disease 2019 (COVID-19). [Read more…]
Stem cell transplants are used to treat certain types of cancer as well as some other conditions. Stem cell transplants have even completely eradicated HIV in some patients.
If you are considering stem cell transplants for your health issues, you will understandably have a lot of questions.
Knowing the right questions to ask about this complex procedure isn’t always that easy, however. We’re here to help with that.
Read on as we look at five important questions to ask your doctor about stem cell transplants. [Read more…]
Stem cells applications are expanding at an accelerating rate, with a search of the world’s largest clinical trial database (ClinicalTrials.gov) revealing that at least 7,797 trials now involve stem cell products or their derivatives. As the world’s largest database of clinical trials, this figure likely contains approximately three-quarters of clinical trials worldwide ― making the total count even higher.
In addition to stem cell products, a growing market has evolved for a diverse range of regenerative medicine products, including cellular therapies, immunotherapies, exosome therapies, biomaterials, tissue engineered products (TEPs), biologics, and more. [Read more…]
With an anticipated enrollment of 440 patients, it will be the world’s largest trial ever completed with an iPSC-derived cell therapeutic.
It’s official. Australian stem cell company Cynata Therapeutics is preparing to test its iPSC-derived cell therapeutic, CYP 004, in a Phase 3 clinical trial enrolling up to 440 patients.
Led by the University of Sydney and funded by the Australian Government National Health and Medical Research Council (NHMRC), the historic trial will assess whether Cynata’s cell therapeutic, CYP-004, has the capacity to improve patient outcomes in osteoarthritis (OA).
CYP-004 is an allogeneic, iPSC-derived mesenchymal stem cell (MSC) product derived using Cynata’s proprietary Cymerus™ technology. [Read more…]
Stem cells are in a position to revolutionize the way doctors treat disease. Among emerging medical technologies, stem cells are the most exciting because of their enormous potential.
In some cases, stem cell research has discovered medical treatments that were thought unimaginable a decade earlier.
There is a lot of public discourse on the ethics of stem cell therapy and certain legal restrictions that limit research, but what scientists are discovering in spite of these hurdles is truly amazing. [Read more…]